M. Stahl (Berlin, Germany), F. Singer (Bern, Switzerland)
Electrical impedance tomography as a clinical monitoring tool in patients with cystic fibrosis
A. Folino (Torino (TO), Italy), S. Beux (Torino (TO), Italy), L. Barrocu (Torino (TO), Italy), I. Esposito (Torino (TO), Italy), B. Crida (Torino (TO), Italy), R. Cotti (Torino (TO), Italy), L. Appendini (Saluzzo (CN), Italy), E. Bignamini (Torino (TO), Italy)
|   |
Electronic nose (E-nose) analysis of exhaled volatile organic compounds (VOCs) distinguishes pediatric patients (pts) with Cystic fibrosis (CF) from healthy controls (HC) and depicts disease status
F. Lucca (Verona, Italy), S. Volpi (Verona, Italy), L. Tenero (Verona, Italy), M. Piazza (Verona, Italy), M. Sandri (Brescia, Italy), M. Cipolli (Verona, Italy), G. Piacentini (Verona, Italy)
| |
Lung Clearance Index (LCI) derived from N2-Multiple Breath Washout (MBW) depicts worsening in airways colonization in pediatric Cystic Fibrosis (CF) patients (pts)
F. Lucca (Verona, Italy), S. Volpi (Verona, Italy), A. Borruso (Verona, Italy), L. Menin (Verona, Italy), E. Pintani (Verona, Italy), M. Cipolli (Verona, Italy)
| |
Shedding light into the black box of infant multiple-breath washout
M. Oestreich (Bern, Switzerland), F. Wyler (Bern, Switzerland), P. Latzin (Bern, Switzerland), K. Ramsey (Bern, Switzerland)
| |
Multicenter feasibility of lung clearance index in preschool children with cystic fibrosis and other lung diseases
M. Stahl (Berlin, Germany), C. Joachim (Heidelberg, Germany), T. Uselmann (Heidelberg, Germany), Y. Yu (Heidelberg, Germany), I. Kirsch (Heidelberg, Germany), C. Berger (Hannover, Germany), C. Stolpe (Hannover, Germany), R. Minso (Hannover, Germany), I. Rudolf (Hannover, Germany), N. Alfeis (Hannover, Germany), L. Liboschick (Lübeck, Germany), D. Tennhardt (Lübeck, Germany), A. Steinmetz (Lübeck, Germany), X. Bovermann (Lübeck, Germany), J. Röhmel (Berlin, Germany), K. Unorji-Frank (Berlin, Germany), F. Dörfler (Berlin, Germany), C. Rückes-Nilges (Giessen, Germany), B. Von Stoutz (Giessen, Germany), L. Naehrlich (Giessen, Germany), M. Kopp (Lübeck, Germany), A. Dittrich (Hannover, Germany), O. Sommerburg (Heidelberg, Germany), M. Mall (Berlin, Germany)
| |
“Lung clearence index”; Can it be a guide for long-term follow up of children with cystic fibrosis who have normal spirometric values?
. Ozsezen (Ankara, Turkey), E. Yalcin (Ankara, Turkey), N. Emiralioglu (Ankara, Turkey), D. Ademhan Tural (Ankara, Turkey), C. Caka (Ankara, Turkey), B. Sunman (Ankara, Turkey), D. Dogru (Ankara, Turkey), U. Ozcelik (Ankara, Turkey), N. Kiper (Ankara, Turkey)
| |
Blood gas analysis to predict survival in patients with cystic fibrosis
J. Kurz (Bern, Switzerland), B. Spycher (Bern, Switzerland), R. Rodriguez (Bern, Switzerland), R. Fischer Biner (Bern, Switzerland), P. Latzin (Bern, Switzerland), F. Singer (Bern, Switzerland)
| |
Performance of impulse oscillometry and spirometry for the diagnosis of acute exacerbations of cystic fibrosis in adults
T. Blin (Tours, France), T. Flament (Tours, France), J. Mankikian (Tours, France), A. Chambellan (Nantes, France), S. Marchand Adam (Tours, France), L. Plantier (Tours, France)
| |
Sleep duration and activity of exacerbated and non-exacerbated cystic fibrosis patients during their hospital stay
C. Linker (Dortmund, Germany), S. Straßburg (Essen, Germany), S. Dietz-Terjung (Essen, Germany), M. Welsner (Essen, Germany), S. Brato (Dortmund, Germany), C. Taube (Essen, Germany), C. Schöbel (Essen, Germany), J. Götze (Dortmund, Germany), G. Weinreich (Essen, Germany)
| |
Rescue of CFTR function impaired by mutations in exon 15
K. Martinovich (Perth (WA), Australia), A. Kicic (Perth (WA), Australia), S. Fletcher (Perth (WA), Australia), S. Wilton (Perth (WA), Australia), S. Stick (Perth (WA), Australia), .. On Behalf Of Arest-Cf (Perth (WA), Australia), &. Waerp (Perth (WA), Australia)
| |
A retrospective observational study: Bidirectional pharmacokinetic interactions between ivacaftor-lumacaftor in cystic fibrosis
E. Schneider (Parkville (VIC), Australia), P. Hanafin (Chapel Hill, United States of America), G. Rao (Chapel Hill, United States of America)
| |
Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting
R. Hofland (Utrecht, Netherlands), B. Aalbers (Utrecht, Netherlands), I. Bronsveld (Utrecht, Netherlands), M. Kruijswijk (Utrecht, Netherlands), S. Schotman (Utrecht, Netherlands), H. Heijerman (Utrecht, Netherlands)
| |
Assessment of Lumacaftor/Ivacaftor therapy on physical activity and exercise tolerance in adults with cystic fibrosis
A. Porcella (Rome, Italy), A. Gramegna (Milan, Italy), M. Di Paolo (Rome, Italy), M. Vicenzi (Milan, Italy), I. Rota (Milan, Italy), C. Biglia (Orbassano, Italy), B. Messore (Orbassano, Italy), E. Leggieri (Rome, Italy), F. Blasi (Milan, Italy), P. Palange (Rome, Italy), D. Savi (Rome, Italy)
| |
Nasal high-flow therapy (NHFT) during exercise in patients with cystic fibrosis (CF): a randomized crossover trial
G. Spoletini (Leeds (West Yorkshire), United Kingdom), R. Watson (Leeds (West Yorkshire), United Kingdom), K. Pollard (Leeds (West Yorkshire), United Kingdom), W. Lim (Leeds (West Yorkshire), United Kingdom), C. Etherington (Leeds (West Yorkshire), United Kingdom), I. Clifton (Leeds (West Yorkshire), United Kingdom), D. Peckham (Leeds (West Yorkshire), United Kingdom)
| |
Vitamin D status correlates with lung function in children and adolescents with cystic fibrosis.
E. Zhekaite (Moscow, Russian Federation), E. Kondratyeva (Moscow, Russian Federation), A. Voronkova (Moscow, Russian Federation), V. Sherman (Moscow, Russian Federation), R. Budzinsky (Moscow, Russian Federation), A. Zodbinova (Moscow, Russian Federation), Y. Melyanovskaya (Moscow, Russian Federation)
| |
European Cystic Fibrosis Society Clinical Trials Network (ECFS-CTN): structure and impact since 2009
S. Van Koningsbruggen-Rietschel (Cologne, Germany), D. Downey (Belfast, United Kingdom), L. Dupont (Leuven, Belgium), F. Dunlevy (Cannes, France), V. Bulteel (Leuven, Belgium), K. Hayes (Belfast, United Kingdom), N. Simmonds (London, United Kingdom), N. Dufeu (Marseille, France), H. Janssens (Rotterdam, Netherlands), D. Sands (Warsaw, Poland), P. De Carli (Paris, France), I. Sermet-Gaudelus (Paris, France), K. De Boeck (Leuven, Belgium), T. Lee (Leeds, United Kingdom), I. Fajac (Paris, France)
| |
Is Pulmonary Medication Adherence affected by disease severity among adult patients with Cystic Fibrosis?
E. Hatziagorou (Thessaloniki, Greece), K. Manika (Thessaloniki, Greece), S. Kyrvasili (Thessaloniki, Greece), E. Kouroukli (Thessaloniki, Greece), E. Sourla (Thessaloniki, Greece), I. Lialias (Thessaloniki, Greece), S. Kotoulas (Thessaloniki, Greece), M. Sionidou (Thessaloniki, Greece), J. Kioumis (Thessaloniki, Greece), J. Tsanakas (Thessaloniki, Greece)
| |
Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease
S. Javad Sayedi (Mashhad, Islamic Republic of Iran), M. Reisi (Mashhad, Islamic Republic of Iran), M. Modaresi (Mashhad, Islamic Republic of Iran), Z. Aghaii (Mashhad, Islamic Republic of Iran), S. Mirlohi (Mashhad, Islamic Republic of Iran), H. Rafiemanesh (Mashhad, Islamic Republic of Iran), G. Azizi (Mashhad, Islamic Republic of Iran)
| |